All data are based on the daily closing price as of April 25, 2025
m
Medy-Tox
086900.KQ
113.78 USD
-0.96
-0.84%
Overview
Last close
113.78 usd
Market cap
748.52M usd
52 week high
187.48 usd
52 week low
77.92 usd
Target price
153.1 usd
Valuation
P/E
N/A
Forward P/E
30.4878
Price/Sales
4.7077
Price/Book Value
2.3241
Enterprise Value
769.10M usd
EV/Revenue
4.8342
EV/EBITDA
28.2049
Key financials
Revenue TTM
159.10M usd
Gross Profit TTM
96.44M usd
EBITDA TTM
28.05M usd
Earnings per Share
N/A usd
Dividend
3.06 usd
Total assets
417.35M usd
Net debt
22.48M usd
About
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.